Form 4: Ovid Therapeutics Director Bart Friedman Acquires 90,000 Stock Options

Ovid Therapeutics director Bart Friedman was granted 90,000 stock options, vesting monthly over three years.

Summary

• Director Bart Friedman of Ovid Therapeutics acquired 90,000 stock options on December 12, 2024.
• The options have an exercise price of $1.06 per share.
• The options will vest in 36 equal monthly installments, contingent on Mr. Friedman's continued service.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with the long-term success of the company.
• The vesting schedule encourages continued service from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the 36-month period in this case, are typical to ensure long-term commitment from the recipient.
• The exercise price of $1.06 is likely based on the market price of Ovid Therapeutics stock at the time of the grant.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, Ovid Therapeutics, director, equity, vesting, Form 4